Patents by Inventor Riyue Bao

Riyue Bao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230256034
    Abstract: The current disclosure provides methods and compositions for treating autoimmune conditions, including allergic conditions such as food allergy. Certain aspects of the disclosure relate to methods for treatment of food allergy comprising administering a composition comprising Phascolarctobacterium faecium and/or Ruminococcus bromii. In some aspects, disclosed are compositions comprising isolated, lyophilized bacteria such as Phascolarctobacterium faecium and/or Ruminococcus bromii.
    Type: Application
    Filed: July 22, 2021
    Publication date: August 17, 2023
    Applicants: THE UNIVERSITY PF CHICAGO, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Cathryn R. NAGLER, Kari NADEAU, Riyue BAO, Lauren Anders HESSER
  • Patent number: 11638728
    Abstract: Provided herein are compositions and methods comprising microbiome biomarkers of responsiveness/resistance to immunotherapy (e.g., anti-PD1/PD-L1 therapy), and diagnostic, prognostic and therapeutic uses thereof. In particular, the amount, identity, presence, and/or ratio of microflora in the microbiome of a subject is used to determine the responsiveness/resistance of the subject to immunotherapy, and/or the microbiome of a subject is manipulated to enhance the responsiveness of the subject to various immunotherapies and co-therapies.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: May 2, 2023
    Assignee: The University of Chicago
    Inventors: Thomas F. Gajewski, Jason Luke, Riyue Bao, Vyara Matson, Jessica Fessler
  • Publication number: 20210386796
    Abstract: The current disclosure provides methods and compositions for treating food allergies, infections, autoimmune conditions, and other allergic conditions. Accordingly, the current disclosure relates to a method for treating an infectious, autoimmune, or allergic disease in a subject comprising administering a composition comprising bacterium Anaerostipes caccae to the subject. Further aspects relate to a method for treating a food allergy or for reducing an allergic response to an allergen or for treating or preventing an anaphylactic response in a subject comprising administering a composition comprising bacterium Anaerostipes caccae and a prebiotic to the subject.
    Type: Application
    Filed: November 5, 2019
    Publication date: December 16, 2021
    Applicants: The University of Chicago, ClostraBio
    Inventors: Cathryn R. NAGLER, Riyue BAO, Dionysios ANTONOPOULOS, John W. COLSON, Lauren Anders HESSER
  • Publication number: 20210177918
    Abstract: Provided herein are compositions and methods comprising microbiome biomarkers of responsiveness/resistance to immunotherapy (e.g., anti-PD1/PD-L1 therapy), and diagnostic, prognostic and therapeutic uses thereof. In particular, the amount, identity, presence, and/or ratio of microflora in the microbiome of a subject is used to determine the responsiveness/resistance of the subject to immunotherapy, and/or the microbiome of a subject is manipulated to enhance the responsiveness of the subject to various immunotherapies and co-therapies.
    Type: Application
    Filed: June 5, 2018
    Publication date: June 17, 2021
    Inventors: Thomas F. Gajewski, Jason Luke, Riyue Bao, Vyara Matson, Jessica Fessler